<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Heimans, Lotte</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">IMPROVED: Final Study Results of Combination Treatment in Patients with Early RA and UA</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">Final results of the Induction Therapy with Methotrexate and Prednisone in Rheumatoid or Very Early Arthritis Disease [IMPROVED] study showed that patients with rheumatoid arthritis and undifferentiated arthritis achieved similarly greater rates of remission after early initial treatment with combination therapy (methotrexate and prednisone). Patients who failed to achieve early remission benefited more when switched to a treatment strategy with adalimumab than with multiple disease modifying antirheumatic drugs, with virtually no radiographic damage progression in all patients.</style></abstract><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>